Search results for "relapsing-remitting"

showing 10 items of 73 documents

Gray matter network reorganization in multiple sclerosis from 7‐Tesla and 3‐Tesla MRI data

2020

[Objective]: The objective of this study was to determine the ability of 7T‐MRI for characterizing brain tissue integrity in early relapsing‐remitting MS patients compared to conventional 3T‐MRI and to investigate whether 7T‐MRI improves the performance for detecting cortical gray matter neurodegeneration and its associated network reorganization dynamics.

AdultMaleDYNAMICS0301 basic medicineNeurosciences. Biological psychiatry. NeuropsychiatryBrain tissueATROPHYYoung Adult03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicineText miningAtrophymedicineHumans3 TGray MatterRC346-429Research ArticlesCerebral CortexCHALLENGESbusiness.industryDISABILITYGeneral NeuroscienceMultiple sclerosisMiddle AgedTissue repairmedicine.diseaseMagnetic Resonance ImagingWhite Matter030104 developmental biologyHealthy individualsFemaleNeurology. Diseases of the nervous systemNeurology (clinical)Nerve NetbusinessNuclear medicine030217 neurology & neurosurgeryRC321-571Research ArticleAnnals of Clinical and Translational Neurology
researchProduct

Evidence of Wallerian degeneration in normal appearing white matter in the early stages of relapsing-remitting multiple sclerosis

2003

Objective: Wallerian degeneration in normal appearing white matter in early relapsing-remitting multiple sclerosis (RRMS), and its correlation with the number of relapses and disease duration. Background Recent pathological studies have demonstrated Wallerian degeneration in normal appearing white matter (NAWM) in multiple sclerosis (MS), in established RRMS, and in chronic MS. However, the presence of Wallerian degeneration early in the disease and its correlation with relapse and with disease duration has not been studied. Methods: We performed proton magnetic resonance spectroscopic imaging in 21 MS patients, and 4 healthy controls, age and gender matched, aged under 45 years, with a max…

AdultMaleIn vivo magnetic resonance spectroscopyWallerian degenerationPathologymedicine.medical_specialtyMagnetic Resonance SpectroscopyTime FactorsNeurologyAdolescentWhite matterCentral nervous system diseaseMultiple Sclerosis Relapsing-RemittingmedicineHumansAspartic AcidMultiple sclerosisBrainmedicine.diseaseMagnetic Resonance ImagingPonsRadiographymedicine.anatomical_structurenervous systemNeurologyCerebellar peduncleCreatinineFemaleNeurology (clinical)Wallerian DegenerationPsychologyJournal of Neurology
researchProduct

Corpus callosum function in verbal dichotic listening: inferences from a longitudinal follow-up of Relapsing-Remitting Multiple Sclerosis patients.

2009

This study conducted a follow-up of 13 early-onset slightly disabled Relapsing-Remitting Multiple Sclerosis (RRMS) patients within an year, evaluating both CC area measurements in a midsagittal Magnetic Resonance (MR) image, and Dichotic Listening (DL) testing with stop consonant vowel (C-V) syllables. Patients showed a significant progressive loss of posterior CC areas (isthmus and splenium) related to increasing EDSS scores and an enhancing right ear advantage (REA) over time. A significant correlation between posterior CC areas and DL scores emerged in both evaluations, being negative for the right and positive for the left ear. The pattern of correlations suggests that the CC can serve …

AdultMaleLinguistics and Languagemedicine.medical_specialtyCognitive NeuroscienceSpleniumExperimental and Cognitive PsychologyAudiologyNeuropsychological TestsCorpus callosumSeverity of Illness IndexLanguage and LinguisticsFunctional LateralityDevelopmental psychologyCorpus CallosumSpeech and HearingYoung AdultMultiple Sclerosis Relapsing-RemittingStop consonantVowelProhibitinsmedicineHumansActive listeningAge of OnsetAnalysis of VarianceDichotic listeningPhonologyCognitionMagnetic Resonance ImagingAcoustic StimulationAuditory PerceptionDisease ProgressionFemalePsychologyFollow-Up StudiesBrain and language
researchProduct

Functional connectivity analysis using whole brain and regional network metrics in MS patients

2016

In the present study we investigated brain network connectivity differences between patients with relapsing-remitting multiple sclerosis (RRMS) and healthy controls (HC) as derived from functional resonance magnetic imaging (fMRI) using graph theory. Resting state fMRI data of 18 RRMS patients (12 female, mean age ± SD: 42 ± 12.06 years) and 25 HC (8 female, 29.2 ± 5.38 years) were analyzed. In order to obtain information of differences in entire brain network, we focused on both, local and global network connectivity parameters. And the regional connectivity differences were assessed using regional network parameters. RRMS patients presented a significant increase of modularity in comparis…

AdultMaleModularity (networks)Resting state fMRIInformation processingBrainCognitionSuperior parietal lobuleMiddle AgedMagnetic Resonance Imaging030218 nuclear medicine & medical imagingCorrelation03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicineImage Processing Computer-AssistedHumansFemaleNerve NetPsychologyInsulaNeuroscience030217 neurology & neurosurgeryClustering coefficient2016 38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC)
researchProduct

Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study

2022

Background and ObjectivesSeveral studies have assessed risk factors associated with the severity of COVID-19 outcomes in people with multiple sclerosis (PwMS). The potential role of disease-modifying therapies (DMTs) and demographic and clinical factors on the risk of acquiring SARS-CoV-2 infection has not been evaluated so far. The objective of this study was to assess risk factors of contracting SARS-CoV-2 infection in PwMS by using data collected in the Italian MS Register (IMSR).MethodsA case-control (1:2) study was set up. Cases included PwMS with a confirmed diagnosis of COVID-19, and controls included PwMS without a confirmed diagnosis of COVID-19. Both groups were propensity score–m…

AdultMaleMultiple SclerosisTime Factors41Dimethyl FumarateSex FactorRelapsing-RemittingSeverity of Illness IndexArticleImmunosuppressive AgentSex FactorsMultiple Sclerosis Relapsing-RemittingRisk FactorsMultiple SclerosiOdds RatioHumansAge Factor36053g COVID-19Fingolimod HydrochlorideSARS-CoV-2NatalizumabRisk FactorAge FactorsCOVID-19Glatiramer AcetateInterferon-betaMiddle AgedMultiple Sclerosis Chronic Progressive323Chronic ProgressiveNeurologyItalyCase-Control StudiesAdult; Age Factors; COVID-19; Case-Control Studies; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis Chronic Progressive; Multiple Sclerosis Relapsing-Remitting; Natalizumab; Odds Ratio; Risk Factors; SARS-CoV-2; Severity of Illness Index; Sex Factors; Time FactorsFemaleNeurology (clinical)Case-Control StudieImmunosuppressive AgentsHuman
researchProduct

NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study

2021

Background: Easily accessible biomarkers enabling the identification of those patients with multiple sclerosis (MS) who will accumulate irreversible disability in the long term are essential to guide early therapeutic decisions. We here examine the utility of serum neurofilament light chain (sNfL) for forecasting relapse-free disability progression and conversion to secondary progressive MS (SPMS) in the prospective Neurofilament and longterm outcome in MS (NaloMS) cohort. Methods: The predictive ability of sNfL at Baseline and sNfL follow-up (FU)/ Baseline (BL) ratio with regard to disability progression was assessed within a development cohort (NaloMS, n=196 patients with relapsing-remitt…

AdultMaleOncologymedicine.medical_specialtyMedicine (General)Logistic regressionGeneral Biochemistry Genetics and Molecular BiologyMultiple sclerosisYoung AdultMultiple Sclerosis Relapsing-RemittingR5-920Neurofilament ProteinsInterquartile rangeInternal medicinemedicineHumansLongitudinal StudiesProspective StudiesRisk factorNeurofilament light chainSPMS transitionDisease progressionClinically isolated syndromebusiness.industryRGeneral MedicineOdds ratioMultiple Sclerosis Chronic ProgressiveConfidence intervalCohortMedicineFemalebusinessBiomarkersResearch PaperCohort studyEBioMedicine
researchProduct

Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study

2009

Background To investigate in a large cohort of patients with multiple sclerosis (MS), lesion load and atrophy evolution, and the relationship between clinical and magnetic resonance imaging (MRI) correlates of disease progression. Methods Two hundred and sixty-seven patients with MS were studied at baseline and two years later using the same MRI protocol. Abnormal white matter fraction, normal appearing white matter fraction, global white matter fraction, gray matter fraction and whole brain fraction, T2-hyperintense, and T1-hypointense lesions were measured at both time points. Results The majority of patients were clinically stable, whereas MRI-derived brain tissue fractions were signifi…

AdultMalePathologymedicine.medical_specialtyAdolescentCentral nervous systemmultiple sclerosisSeverity of Illness IndexLesion loadWhite matterCentral nervous system diseaseYoung AdultDegenerative diseaseAtrophyMultiple Sclerosis Relapsing-RemittingatrophyRisk FactorsT2 lesionsmedicinefollow upHumansAgedmedicine.diagnostic_testbusiness.industryMultiple sclerosisBrain AtrophyBrainMagnetic resonance imagingMiddle AgedMultiple Sclerosis Chronic Progressivelesion loadmedicine.diseaseMagnetic Resonance Imagingmedicine.anatomical_structureCross-Sectional StudiesLogistic ModelsNeurologymultiple sclerosiMultivariate AnalysisDisease ProgressionFemaleSettore MED/26 - NeurologiaNeurology (clinical)businessFollow-Up StudiesMRI
researchProduct

Cognitive impairment in multiple sclerosis can be predicted by imaging early in the disease.

2008

Background: Cognitive impairment is common in multiple sclerosis (MS) and adds significantly to the burden of the disease. The ability to predict future cognitive impairment from imaging obtained at disease onset has not been investigated. Methods: 62 patients imaged within 3 months of a clinically isolated syndrome were assessed neuropsychologically 7 years later. Baseline and periodic MRI measures of lesions, atrophy and normal-appearing white and grey matter were regressed against neuropsychological scores to explore the best predictors of cognitive outcome. Results: 28 patients had developed clinically definite MS at follow-up and a further nine met revised McDonald criteria for MS. Def…

AdultMalePathologymedicine.medical_specialtyPediatricsMagnetic Resonance SpectroscopyAdolescentGrey matterNeuropsychological TestsCerebral VentriclesWhite matterCohort StudiesDisability EvaluationAtrophyMultiple Sclerosis Relapsing-RemittingPredictive Value of TestsmedicineHumansProspective StudiesNeurologic ExaminationAspartic AcidClinically isolated syndromeMultiple sclerosisCognitive disorderNeuropsychologyBrainMcDonald criteriaDipeptidesMiddle Agedmedicine.diseaseCognitive impairment: multiple sclerosisMagnetic Resonance ImagingPsychiatry and Mental healthmedicine.anatomical_structureSurgeryFemaleNeurology (clinical)AtrophyPsychologyCognition DisordersInositolFollow-Up StudiesJournal of neurology, neurosurgery, and psychiatry
researchProduct

Quality of life, depression and fatigue in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon bet…

2011

Background: The precise relationships among quality of life, depression, fatigue and cognitive impairment in multiple sclerosis (MS) are complex and poorly understood. Objective: To assess the effects of subcutaneous interferon beta-1a on quality of life, depression and fatigue over 3 years in the COGIMUS study, and to examine the relationship between these outcomes and baseline cognitive status. Methods: COGIMUS was an observational 3-year trial assessing cognitive function in 459 patients with relapsing–remitting MS treated with subcutaneous interferon beta-1a. Results: In total, 331 patients completed the study (168 received interferon beta-1a, 44 µg subcutaneously three times weekly, a…

AdultMaleQuality of lifeLongitudinal studymedicine.medical_specialtyInjections Subcutaneousmultiple sclerosisRelapsing-Remitting Multiple SclerosisInterferon beta 1aYoung AdultMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicQuality of lifeInternal medicinemedicineHumansYoung adultFatigueDepression (differential diagnoses)AgedDepressionbusiness.industryCognitive function; Depression; Fatigue; Interferon beta 1a; Longitudinal study; Quality of life; Relapsing-Remitting Multiple SclerosisMultiple sclerosisCognitive disorderInterferon beta-1aInterferon-betaMiddle Agedmedicine.diseaseClinical trialNeurologyPhysical therapymultiple sclerosis cognition interferon betaFemaleSettore MED/26 - NeurologiaCognitive functionNeurology (clinical)Longitudinal studyCognition DisordersbusinessInterferon beta-1amedicine.drugMultiple Sclerosis Journal
researchProduct

Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.

2009

OBJECTIVE: Recent findings support greater efficacy of early vs. delayed interferon beta (IFNbeta) treatment in patients with a first clinical event suggestive of multiple sclerosis (MS). We aimed to evaluate the effectiveness of early IFNbeta treatment in definite relapsing-remitting MS (RRMS) and to assess the optimal time to initiate IFNbeta treatment with regard to the greatest benefits on disability progression. METHODS: A cohort of 2,570 IFNbeta-treated RRMS patients was prospectively followed for up to 7 years in 15 Italian MS Centers. A Cox proportional hazards regression model adjusted for propensity score (PS) quintiles was used to assess differences between groups of patients wit…

AdultMaleTime FactorsMultiple Sclerosis; Interferon betaInterferon-beta.Interferon betaCohort StudiesYoung AdultMultiple Sclerosis Relapsing-RemittingTreatment Outcomeobservational study multiple sclerosis interferon treatment earlySickness Impact ProfileMultiple SclerosiQuality of LifeHumansFemaleSettore MED/26 - NeurologiaProspective StudiesFollow-Up Studies
researchProduct